Nearly half of clientele who completed 56 weeks of care with Orexigen Therapeutics Inc's test obesity treatment, Contrave, lost at least 10 percent of their weight in a late-stage study and the drug also appeared to help cholesterol and blood sugar levels.

More: - Read the rest here